Grufity logo
Grufity logo

Latest SILVERARC CAPITAL MANAGEMENT, LLC Stock Portfolio

$962Million | No. of Holdings #65

SILVERARC CAPITAL MANAGEMENT, LLC Performance

2026 Q2+13.47%
YTD+23.27%
2025+53.51%

About SILVERARC CAPITAL MANAGEMENT, LLC and 13F Hedge Fund Stock Holdings

SILVERARC CAPITAL MANAGEMENT, LLC is a hedge fund based in Boston, MA. On 2026-08-13, the fund reported it's updated stock portfolio. In the 13F Holdings report, SILVERARC CAPITAL MANAGEMENT, LLC reported an equity portfolio of $962.2 Millions as of 30 Jun, 2026. <br><br> The top stock holdings of SILVERARC CAPITAL MANAGEMENT, LLC are , CELC, COGT. The fund has invested 5.7% of it's portfolio in ASCENDIS PHARMA A/S and 5.4% of portfolio in CELCUITY INC. <br><br> The fund managers got completely rid off KALVISTA PHARMACEUTICALS INC (KALV), NUVALENT INC (NUVL) and ASCENDIS PHARMA A/S (ASND) stocks. They significantly reduced their stock positions in ALKERMES PLC (ALKS), SPYRE THERAPEUTICS INC (AGLE) and DISC MEDICINE INC. SILVERARC CAPITAL MANAGEMENT, LLC opened new stock positions in ASCENDIS PHARMA A/S, ALX ONCOLOGY HLDGS INC (ALXO) and ACLARIS THERAPEUTICS INC (ACRS). The fund showed a lot of confidence in some stocks as they added substantially to IBIO INC (IBIO), OVID THERAPEUTICS INC (OVID) and ORUKA THERAPEUTICS INC.
SILVERARC CAPITAL MANAGEMENT, LLC Equity Portfolio Value
Last Reported on: 13 Aug, 2026
$962Million
  as of Aug 13, 2026

SILVERARC CAPITAL MANAGEMENT, LLC Annual Return Estimates Vs S&P 500

Our best estimate is that SILVERARC CAPITAL MANAGEMENT, LLC made a return of 13.47% in the last quarter. In trailing 12 months, it's portfolio return was 77.24%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
ascendis pharma a/s55,006,700
enliven therapeutics inc24,836,100
sagimet biosciences inc22,631,100
definium therapeutics inc18,816,000
alx oncology hldgs inc11,891,600
veradermics inc11,679,300
avalyn pharmaceuticals inc10,879,600
aclaris therapeutics inc10,296,900
New stocks bought by SILVERARC CAPITAL MANAGEMENT, LLC

Additions

Ticker% Inc.
ibio inc1,457
ovid therapeutics inc210
oruka therapeutics inc133
veracyte inc76.96
compass pathways plc67.79
c4 therapeutics inc58.6
immunovant inc49.45
celcuity inc39.98
Additions to existing portfolio by SILVERARC CAPITAL MANAGEMENT, LLC

Reductions

Ticker% Reduced
alkermes plc-75.34
spyre therapeutics inc-67.87
disc medicine inc-57.76
zenas biopharma inc-55.12
crescent biopharma inc.-54.71
kodiak sciences inc-44.93
monte rosa therapeutics inc-44.64
abivax sa-43.94
SILVERARC CAPITAL MANAGEMENT, LLC reduced stake in above stock

Sold off

Ticker$ Sold
kalvista pharmaceuticals inc-57,902,100
compass therapeutics inc-4,544,370
neumora therapeutics inc.-1,595,400
climb bio inc-4,691,620
zura bio ltd-3,335,870
annexon inc-2,750,390
centessa pharmaceuticals plc-18,523,200
fulcrum therapeutics inc-3,221,010
SILVERARC CAPITAL MANAGEMENT, LLC got rid off the above stocks

Sector Distribution

SILVERARC CAPITAL MANAGEMENT, LLC has about 65.6% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare65.6
Others33.5

Market Cap. Distribution

SILVERARC CAPITAL MANAGEMENT, LLC has about 3.4% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • UNALLOCATED
  • SMALL-CAP
  • LARGE-CAP
  • MICRO-CAP
Category%
MID-CAP37.5
UNALLOCATED33.2
SMALL-CAP23
LARGE-CAP3.4
MICRO-CAP2.6

Stocks belong to which Index?

About 49.5% of the stocks held by SILVERARC CAPITAL MANAGEMENT, LLC either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
  • S&P 500
Index%
Others50.5
RUSSELL 200048.3
S&P 5001.2
Top 5 Winners (%)%
URGN
urogen pharma ltd
97.7 %
CMPS
compass pathways plc
94.6 %
fractyl health inc
72.2 %
GH
guardant health inc
61.8 %
CERS
cerus corp
56.4 %
Top 5 Winners ($)$
URGN
urogen pharma ltd
26.4 M
GLUE
monte rosa therapeutics inc
12.1 M
oruka therapeutics inc
11.6 M
RYTM
rhythm pharmaceuticals inc
7.4 M
dianthus therapeutics inc
7.1 M
Top 5 Losers (%)%
RCKT
rocket pharmaceuticals inc
-83.5 %
adagio med hldgs inc
-41.0 %
INSM
insmed inc
-34.1 %
ORIC
oric pharmaceuticals inc
-12.1 %
CELC
celcuity inc
-7.2 %
Top 5 Losers ($)$
CELC
celcuity inc
-4.1 M
INSM
insmed inc
-2.0 M
ORIC
oric pharmaceuticals inc
-1.7 M
SNDX
syndax pharmaceuticals inc
-1.6 M
IMNM
immunome inc
-1.3 M

SILVERARC CAPITAL MANAGEMENT, LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of SILVERARC CAPITAL MANAGEMENT, LLC

SILVERARC CAPITAL MANAGEMENT, LLC has 65 stocks in it's portfolio. About 42.3% of the portfolio is in top 10 stocks. CELC proved to be the most loss making stock for the portfolio. URGN was the most profitable stock for SILVERARC CAPITAL MANAGEMENT, LLC last quarter.

$898.52MTotal Value
87.00Positions
13 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of SILVERARC CAPITAL MANAGEMENT, LLC, last reported on 13 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ASND
Ascendis Pharma A/S

Ascendis Pharma A/S

ASND
SILVERARC CAPITAL MANAGEMENT, LLC's holding in Ascendis Pharma A/S over time
0%0.00
$0.00
0%
decreased 100 percentsold off
CGEN
Compugen Ltd

Compugen Ltd

CGEN
SILVERARC CAPITAL MANAGEMENT, LLC's holding in Compugen Ltd over time
0.71%3,184,260
$6.81M
0.71%
decreased 3.97 percentreduced
CMPS
Compass Pathways Plc

Compass Pathways Plc

CMPS
SILVERARC CAPITAL MANAGEMENT, LLC's holding in Compass Pathways Plc over time
0.74%503,382
$7.12M
0.74%
increased 67.79 percentadded